Journal
Journal of Clinical Oncology
Publication Date
7-1-2024
Volume
42
Issue
19
First Page
2250
Last Page
2256
Document Type
Open Access Publication
DOI
10.1200/JCO.23.02329
Rights and Permissions
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. J Clin Oncol. 2024 Jul 1;42(19):2250-2256. doi: 10.1200/JCO.23.02329. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Budde, Lihua E; Bartlett, Nancy L; and et al., "Durable responses with mosunetuzumab in relapsed/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: Extended follow-up of a phase I/II study." Journal of Clinical Oncology. 42, 19. 2250 - 2256. (2024).
https://digitalcommons.wustl.edu/oa_4/4409
Additional Links
Supplemental material is available for this article at publisher site.
